Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754975 | 1.00 | ALDH1A1 (0.45) | ALDH1A1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL6754979 | 1.00 | ALDH1A1 (0.45) | ALDH1A1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL6756331 | 0.85 | HRH3 (0.40) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6756327 | 0.85 | HRH3 (0.40) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6756330 | 0.85 | HRH3 (0.40) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6754937 | 0.84 | GAA (0.43) | ALDH1A1LMNAKDM4E | |
| SCHEMBL6754938 | 0.84 | GAA (0.43) | ALDH1A1LMNAKDM4E | |
| SCHEMBL6754941 | 0.84 | GAA (0.43) | ALDH1A1LMNAKDM4E | |
| SCHEMBL6194004 | 0.76 | GOT1 (0.47) | DRD2DRD3HTR1AMAPTNPSR1 | |
| SCHEMBL6194616 | 0.74 | ADRA1A (0.44) | DRD2CYP3A4CYP2C19ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | disclosed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-0966473-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-07-24 | — | — | EP | disclosed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-0966473-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038194-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | ALDH1A1 1076/4885DRD2 163/4885DRD3 177/4885 |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | SLCO2B1, SLCO1B1, CYP21A2 | ALDH1A1 62/4885DRD2 3859/4885DRD3 3074/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | ALDH1A1 595/4885DRD2 85/4885DRD3 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.